Effect of Clomiphene Citrate on Uterine Blood Fow in Women With Unexplained Delayed Conception
Effect of Clomiphene Citrate on Uterine Hemodynamics in Women With Unexplained Infertility
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Greater Cairo
-
Cairo, Greater Cairo, Egypt, 11956
- Department of Obstetrics and Gynecology, Kasr Al-Ainy hospital, Cairo University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Unexplained infertility
- Body mass index less than 30
- Regular menstruation
- Normal pelvic examination and ultrasonography
Exclusion Criteria:
- History of pelvic operations including cesarean section
- History of pelvic inflammatory disease
- Endometriosis
- Pelvic pathology including uterine fibroids
- General disease or medication that could potentially affect pelvic blood flow
- Smoking
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Crossover
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Flow index of the endometrial region
Time Frame: Day 22 to 24 of the menstrual cycle
|
Flow index of the endometrial region was measured by a researcher
|
Day 22 to 24 of the menstrual cycle
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Vascularization index of the endometrial region
Time Frame: Day 22 to 24 of the menstrual cycle
|
Vascularization index of the endometrial region was measured by a researcher
|
Day 22 to 24 of the menstrual cycle
|
|
Vascularization flow index of the endometrial region
Time Frame: Day 22 to 24 of the menstrual cycle
|
Vascularization flow index of the endometrial region was measured by a researcher
|
Day 22 to 24 of the menstrual cycle
|
|
Vascularization flow index of the sub-endometrial region
Time Frame: Day 22 to 24 of the menstrual cycle
|
Vascularization flow index of the sub-endometrial region was measured by a researcher
|
Day 22 to 24 of the menstrual cycle
|
|
Flow index of the sub-endometrial region
Time Frame: Day 22 to 24 of the menstrual cycle
|
Flow index of the sub-endometrial region was measured by a researcher
|
Day 22 to 24 of the menstrual cycle
|
|
Vascularization index of the sub-endometrial region
Time Frame: Day 22 to 24 of the menstrual cycle
|
Vascularization index of the sub-endometrial region was measured by a researcher
|
Day 22 to 24 of the menstrual cycle
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Eman Omran, M.D., Cairo university
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 4588
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infertility, Female
-
NCT07398924CompletedUnexplained Infertility | Female Infertility | Anovulatory Infertility
-
NCT03670758UnknownUnexplained Female Infertility
-
NCT01331395TerminatedPrimary Female Infertility | Secondary Female Infertility
-
NCT01936077CompletedInfertility, Female Infertility, Male Infertility
-
NCT07404969RecruitingInfertility Unexplained | Infertility (IVF Patients) | Idiopathic Infertility | Infertility Female | Infertility Assisted Reproductive Technology
-
NCT06174298RecruitingInfertility | Infertility,Female | Infertility Unexplained | Infertility of Uterine Origin | Infertility; Female, Nonimplantation
-
NCT02107521TerminatedMale Infertility | Female Infertility
-
NCT04184323WithdrawnUterine Diseases | Endometriosis | Infertility Unexplained | Endometrial Diseases | Infertility; Female, Nonimplantation
-
NCT00315029CompletedPregnancy | Male Infertility | Female Infertility
-
NCT02195947CompletedFemale Infertility Due to Diminished Ovarian Reserve
Clinical Trials on Vascularization indices observation
-
NCT04682496Completed
-
NCT07233551Not yet recruitingAcute Pancreatitis (AP) | Inflammatory Indices
-
NCT06612385Not yet recruitingPlatelet Indices | Platelet Ratios
-
NCT03466853Unknown
-
NCT06791200Not yet recruiting
-
NCT03172013Unknown
-
NCT06127420Active, not recruiting
-
NCT06175572CompletedMyocardial Ischemia | Coronary Artery Disease | Coronary Microvascular Dysfunction
-
NCT05517811RecruitingColorectal Cancer | Esophageal Cancer | Lung Adenocarcinoma | Pancreas Cancer | Liver Cancer | Biliary Cancer | Control